Champion H C, Bivalacqua T J, Friedman D E, Zadina J E, Kastin A J, Kadowitz P J
Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Peptides. 1998;19(9):1595-602. doi: 10.1016/s0196-9781(98)00110-7.
We have recently shown that endomorphin 1, an endogenous ligand for the mu-opioid receptor, and nociceptin (Orphanin FQ; OFQ), an endogenous ligand for the ORL1 receptor, have substantial vasodilator activity in the hindquarters vascular bed of the rat. In the present study, the role of nitric oxide, vasodilator prostaglandins, and the opening of K+ ATP channels in mediating vasodilator responses to endomorphin 1, PL017, and DAMGO was investigated in the regional vascular bed in the rat. Under constant-flow conditions, injections of the mu-selective agonists endomorphin 1, PL017 ([N-MePhe3,D-Pro4]-morphiceptin), and DAMGO, and the ORL1 receptor agonist nociceptin/ OFQ produced dose-dependent decreases in hindquarters perfusion pressure. Vasodilator responses to endomorphin 1, PL017, and DAMGO, and the endothelium-dependent vasodilators acetylcholine and adrenomedullin were attenuated by the nitric oxide synthase inhibitor L-NAME (50 mg/kg IV) at a time when vasodilator responses to nociceptin/OFQ were not altered. Vasodilator responses to isoproterenol and prostaglandin E1, agents known to increase cAMP levels, and the nitric oxide donor DEA/NO were not altered by the nitric oxide synthase inhibitor. Responses to endomorphin 1, PL017, DAMGO, and nociceptin/OFQ were not altered by sodium meclofenamate at a time when vasodilator responses to arachidonic acid were reduced significantly or after administration of U-37883A at a time when vasodilator responses to levcromakalim were reduced significantly. The results of these studies indicate that responses to endomorphin 1, PL017, and DAMGO are mediated in large part by the release of nitric oxide, while responses to nociceptin/OFQ are mediated by an L-NAME-insensitive mechanism. Moreover, these results demonstrate that responses to these peptides are not mediated by the release of vasodilator prostaglandins or the opening of K+ATP channels the hindquarters vascular bed.
我们最近发现,μ-阿片受体的内源性配体脑啡肽1和孤啡肽受体(ORL1)的内源性配体孤啡肽(痛敏肽;OFQ)在大鼠后肢血管床具有显著的血管舒张活性。在本研究中,我们在大鼠局部血管床中研究了一氧化氮、血管舒张性前列腺素以及K⁺ATP通道开放在介导对脑啡肽1、PL017和DAMGO的血管舒张反应中的作用。在恒流条件下,注射μ-选择性激动剂脑啡肽1、PL017([N-甲基苯丙氨酸³,D-脯氨酸⁴]-强啡肽原)和DAMGO,以及ORL1受体激动剂孤啡肽/OFQ,会使后肢灌注压呈剂量依赖性降低。一氧化氮合酶抑制剂L-NAME(50 mg/kg静脉注射)可减弱对脑啡肽1、PL017和DAMGO以及内皮依赖性血管舒张剂乙酰胆碱和肾上腺髓质素的血管舒张反应,而此时对孤啡肽/OFQ的血管舒张反应未改变。一氧化氮合酶抑制剂不会改变对异丙肾上腺素和前列腺素E1(已知可提高cAMP水平的药物)以及一氧化氮供体DEA/NO的血管舒张反应。在显著降低对花生四烯酸的血管舒张反应时,甲氯芬那酸钠不会改变对脑啡肽1、PL017、DAMGO和孤啡肽/OFQ的反应;在显著降低对左卡尼汀的血管舒张反应时,给予U-37883A后也不会改变对上述物质的反应。这些研究结果表明,对脑啡肽1、PL017和DAMGO的反应在很大程度上是由一氧化氮的释放介导的,而对孤啡肽/OFQ的反应是由一种对L-NAME不敏感的机制介导的。此外,这些结果表明,对这些肽的反应不是由血管舒张性前列腺素的释放或后肢血管床中K⁺ATP通道的开放介导的。